Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly has acquired worldwide rights to Locemia’s intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin.
Novartis has announced new late-breaking data demonstrating that Cosentyx (secukinumab) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.
Allergan’s researchers have presented data at IDWeek from the International Network for Optimal Resistance Monitoring (INFORM) program that monitors the prevalence of resistant bacteria and changing trends of resistance, as well as the in vitro activity of antibiotics against these pathogens.
A research-based healthcare company, Roche, has bought Adheron Therapeutics
Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan’s supplemental New Drug Application (sNDA), for MRSA.
National Institutes of Health (NIH) has launched a new phase of the Breast Cancer and the Environment Research Program (BCERP), focused on prevention.
U.S. Food & Drug Administration (FDA) has updated information on Drug Shortages.
A federal judge in the U.S. District Court for the District of South Dakota yesterday granted the U.S. Food and…
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, have announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study.